ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 270 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $3,133 | +41.3% | 130,800 | +11.0% | 0.01% | +66.7% |
Q1 2023 | $2,217 | -55.9% | 117,800 | -62.7% | 0.00% | -57.1% |
Q4 2022 | $5,026 | -99.2% | 315,700 | +737.4% | 0.01% | +600.0% |
Q3 2022 | $617,000 | +75.8% | 37,700 | +160.0% | 0.00% | – |
Q1 2022 | $351,000 | -97.7% | 14,500 | -97.5% | 0.00% | -100.0% |
Q1 2021 | $14,990,000 | +53.7% | 581,000 | +218.5% | 0.02% | +72.7% |
Q4 2020 | $9,751,000 | -12.3% | 182,400 | -32.3% | 0.01% | 0.0% |
Q3 2020 | $11,117,000 | +104.4% | 269,500 | +140.2% | 0.01% | +120.0% |
Q2 2020 | $5,438,000 | +111.7% | 112,200 | +84.5% | 0.01% | +150.0% |
Q1 2020 | $2,569,000 | -91.8% | 60,800 | -91.7% | 0.00% | -91.7% |
Q4 2019 | $31,272,000 | +912.7% | 731,000 | +752.0% | 0.02% | +700.0% |
Q3 2019 | $3,088,000 | -68.1% | 85,800 | -85.6% | 0.00% | -72.7% |
Q4 2018 | $9,666,000 | +170.2% | 597,800 | +247.0% | 0.01% | +175.0% |
Q3 2018 | $3,577,000 | +5.0% | 172,300 | -22.8% | 0.00% | +100.0% |
Q2 2018 | $3,408,000 | – | 223,200 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |